INTRODUCTION

Glioblastoma represents 15-20% of brain tumors and 50% of all gliomas (1). A characteristic histopathologic hallmark of glioblastoma is marked cytologic heterogeneity of astrocytic tumor cells associated with necrosis and/or vascular endothelial proliferation (2, 3). Molecular biologic studies indicate that glioblastoma is the common end point in the progression of grade 2 (low-grade) or grade 3 (anaplastic) astrocytomas (4, 5). In the revised WHO classification of tumors of the central nervous system, glioblastoma is classified under the group of astrocytic tumors, grade 4, as opposed to its prior classification under embryonal tumors (6).

Recent clinical and molecular studies indicate the two different genetic pathways leading to the development of glioblastoma; (a) final progression of astrocytoma and de novo formation. To define the mutual relationships of cytogenetic changes in the pathogenesis of glioblastoma, molecular histopathologic alterations of p53 and epidermal growth factor receptor (EGFR) were evaluated by single stranded conformational polymorphism, reverse transcriptase-polymerase chain reaction and immunohistochnometric stains in 15 primary and 21 secondary glioblastomas. Mutations in p53 gene and positive immunoreactivity to p53 protein (DO1) were more prevalent in secondary glioblastomas than in primary glioblastomas. A correlation between p53 mutations and p53 immunopositivities in glioblastomas was observed in 83.3% of the cases. All cases with positive p53 immunoreactivities showed p53 mutations; however, 13.9% of glioblastomas with p53 immunopositivities lacked the relevant mutations. EGFR amplifications were detected in 73.3% of primary glioblastomas and 9.5% of secondary glioblastomas (p<0.001). The concurrence of p53 mutation and EGFR amplification was revealed in only 2 out of 15 primary glioblastomas and none among the secondary glioblastomas. Immunoreactivities for EGFR were noted in 66.7% of primary glioblastomas and in 9.5% of secondary glioblastomas (p<0.001). A correlation between EGFR amplification and EGFR immunopositivity in glioblastomas was observed in 91.7% of the cases. These data indicate that EGFR amplification and p53 mutations are two independent genetic events in the development of glioblastomas.

Key Words: Glioblastoma; Protein, p53; Receptor, Epidermal Growth Factor; Immunohistochemistry

p53 Mutation and Epidermal Growth Factor Receptor Overexpression in Glioblastoma

Recent molecular studies indicate two different genetic pathways leading to the development of glioblastoma; (a) final progression of astrocytoma and de novo formation. To define the mutual relationships of cytogenetic changes in the pathogenesis of glioblastoma, molecular histopathologic alterations of p53 and epidermal growth factor receptor (EGFR) were evaluated by single stranded conformational polymorphism, reverse transcriptase-polymerase chain reaction and immunohistochnometric stains in 15 primary and 21 secondary glioblastomas. Mutations in p53 gene and positive immunoreactivity to p53 protein (DO1) were more prevalent in secondary glioblastomas than in primary glioblastomas. A correlation between p53 mutations and p53 immunopositivities in glioblastomas was observed in 83.3% of the cases. All cases with positive p53 immunoreactivities showed p53 mutations; however, 13.9% of glioblastomas with p53 immunopositivities lacked the relevant mutations. EGFR amplifications were detected in 73.3% of primary glioblastomas and 9.5% of secondary glioblastomas (p<0.001). The concurrence of p53 mutation and EGFR amplification was revealed in only 2 out of 15 primary glioblastomas and none among the secondary glioblastomas. Immunoreactivities for EGFR were noted in 66.7% of primary glioblastomas and in 9.5% of secondary glioblastomas (p<0.001). A correlation between EGFR amplification and EGFR immunopositivity in glioblastomas was observed in 91.7% of the cases. These data indicate that EGFR amplification and p53 mutations are two independent genetic events in the development of glioblastomas.

Key Words: Glioblastoma; Protein, p53; Receptor, Epidermal Growth Factor; Immunohistochemistry
The aims of this study are to investigate molecular genetic abnormalities and their correlation to clinical criteria of primary and secondary glioblastomas and to define the mutual relationships between p53 mutation and EGFR amplification.

MATERIALS AND METHODS

Tumor samples

All tumor specimens were obtained from patients undergoing therapeutic operation for brain tumors at Chonnam National University Hospital from 1993 to 1998. Samples consisted of fresh-frozen tissues and paraffin-embedded tissue blocks, which were selected based on the adequacy for the molecular biologic and immunohistochemical studies.

Of the 36 cases, 15 patients had a clinical history of less than 3 months and were designated as primary glioblastomas. Twenty-one patients had secondary glioblastomas. Previous operations with initial histopathologic diagnosis of low grade astrocytomas and anaplastic astrocytomas were performed in 8 and 13 patients, respectively. The details of the clinical histories are shown in Table 1 and 2.

Immunohistochemistry for p53 and EGFR proteins

Paraffin-embedded tissue slices, 6 µm in thickness, were immunostained by the avidin-biotin peroxidase (ABC) method (21). Monoclonal antibodies for DO1 (Santa Cruz, U.S.A.) and EGFR-NCL (Novocastra, UK) were used at a titer of 1:100. DO1 binds to both mutant and wild type p53 proteins, and EGFR-NCL attaches to the extracellular ligand-binding domain of EGFR (22). The tissue slices were deparaffinized with xylene. Endogenous peroxidase activity was quenched by incubation in 0.3% hydrogen peroxide in 10% methanol. The tissue slices were hydrated with graded alcohol, treated with 10% normal goat serum for 30 min, and then incubated with primary antibodies overnight at a temperature of 4 °C. They were incubated with biotinylated anti-mouse IgG for 30 min at room temperature. The tissue slices for p53 protein immunostaining were incubated with streptavidin-alkaline phosphatase for 1 hr and developed with fast red TR salt (FRT). EGFR-labeled tissue slices were incubated with 1% avidin-biotinylated horseradish peroxidase in 10% normal goat serum for 1 hr at room temperature and developed in a mixture of 0.4 mg/mL diaminobenzidine (DAB) in 0.1% hydrogen peroxide solution for 40 sec. For negative controls, the primary antibodies were omitted in the process of immunostaining. All immunostained tissues were counterstained with hematoxylin solution for 5 min. After dehydration, the tissue was sealed with a universal mount (Research Genetics, U.S.A.) and examined under a light microscope. Nuclear staining of p53 was scored semi-quantitatively by counting 1,000 cells in the most prominently stained area of the tissue slides (23). Staining of cell membrane for EGFR was marked as + or - in both low grade and high grade areas of the tissue slides (24).

SSCP analysis for p53 mutations

DNA was extracted from paraffin sections. For samples with positive immunostaining with DO1 antibody, the same areas were chosen for DNA extraction. For samples with negative immunostaining, DNA was extracted from

Table 1. Clinical data and molecular genetic alterations of cases with primary glioblastomas

| Case number | Age (yr)/Sex | Site | Mutation* | p53 | IHCL-I (%) | EGFR | Gene amplification | IHCL | IHCH |
|-------------|-------------|------|-----------|-----|-----------|------|------------------|------|------|
| 1           | 54/M        | P    | -         | 0   | +         | +    | +                | +    | +    |
| 2           | 47/M        | F    | -         | 0   | +         | +    | +                | +    | +    |
| 3           | 47/M        | FP   | -         | 0   | -         | -    | -                | -    | -    |
| 4           | 53/M        | F    | 5/6       | 3.5 | +         | +    | +                | +    | +    |
| 5           | 46/M        | F    | -         | 0   | -         | -    | -                | -    | -    |
| 6           | 39/F        | TP   | -         | 1.8 | ±         | -    | -                | -    | -    |
| 7           | 35/M        | Th   | 7         | 2.7 | +         | +    | +                | +    | +    |
| 8           | 48/M        | F    | -         | 0   | ±         | -    | -                | -    | -    |
| 9           | 68/M        | O    | -         | 0   | +         | +    | +                | +    | +    |
| 10          | 53/F        | FP   | -         | 0   | +         | -    | -                | -    | -    |
| 11          | 61/F        | TP   | -         | 7   | 12.3      | -    | -                | -    | -    |
| 12          | 42/F        | F    | -         | 8.1 | -         | -    | -                | -    | -    |
| 13          | 56/M        | O    | -         | 0   | -         | +    | +                | +    | +    |
| 14          | 55/M        | TP   | -         | 0   | +         | +    | +                | +    | +    |
| 15          | 49/F        | F    | -         | 0   | -         | -    | -                | -    | -    |

Sex: M (male), F (female); Site: F (frontal), P (parietal), T (temporal), O (occipital), Th (thalamic)

*: exons, ±: equivocal amplification interpreted as - (negative) in case 6, + (positive) in case 8

IHC-LI, labeling index by immunohistochemistry; IHCL, immunohistochemistry in low-grade area; IHCH, immunohistochemistry in high-grade area.
the lesion which was historically typical of a glioblastoma, avoiding the peripheral infiltration zone. Primers for exons 4-9 of p53 were synthesized (Life Tec, Korea) according to published sequences (25). Details of primers are shown in Table 3. Polymerase chain reaction (PCR)-single stranded conformational polymorphism (SSCP) analysis was performed on 50 μL of PCR mixture containing PCR reaction buffer (10 mM Tris-HCl, pH 8.8 at 25°C, 1.5 mM MgCl₂, 50 mM KCl, 0.1% Triton X-100), 10 pmol of each primer, 50 M dNTPs, 3 μL template DNA, 1 U DNA polymerase, and 0.1 Ci -32P dCTP (NEN, U.S.A.).

After adding 20 μL of mineral oil (Sigma, U.S.A.), 35 cycles were executed. Each cycle consisted of denaturation (94°C) for 1 min, annealing for 60 sec (58°C for exons 5/6 and 8/9, and 64°C for exons 4 and 7), and extension for 2 min (72°C), and was carried out in an automated DNA Thermal Cycler (Perkin-Elmer, France). Forty microliter of stop buffer (95% formamide, 10 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol) was added to the PCR product, and 2 μL of the final mixture was sampled. Samples were heated at 95°C for 5 min and immediately loaded onto a 6% non-denaturating polyacrylamide gel containing 6% glycerol. Gels were run at 30 W for 3 hr, cooled by fan at room temperature, dried at 60°C, and autoradiographed for 12-48 hr.

Table 3. The oligonucleotide primers used to amplify exons 4-9 of p53 gene in polymerase chain reaction (5'-3')

| Exon (s) | Upstream | Downstream |
|---------|----------|------------|
| 4       | ATC-TAC-AGT-CCC-CCT-TGC-GG | GCA-CTG-GAT-GCA-AGT-CA |
| 5/6     | TC-CTC-TCG-CTG-TAG-TAC-TC | AGT-TGC-AAA-CGA-GCT-CTC-AG |
| 7       | GTG-TGG-CTC-CCT-AGG-TTG-GC | CAA-GTG-CTG-CCT-GAC-CTG-GA |
| 8/9     | CCT-ATC-CTG-AGT-AGT-AT | CCA-AGA-CTT-CTG-ACC-TGA-AG |

the lesion which was historically typical of a glioblastoma, avoiding the peripheral infiltration zone. Primers for exons 4-9 of p53 were synthesized (Life Tec, Korea) according to published sequences (25). Details of primers are shown in Table 3. Polymerase chain reaction (PCR)-single stranded conformational polymorphism (SSCP) analysis was performed on 50 μL of PCR mixture containing PCR reaction buffer (10 mM Tris-HCl, pH 8.8 at 25°C, 1.5 mM MgCl₂, 50 mM KCl, 0.1% Triton X-100), 10 pmol of each primer, 50 μM dNTPs, 3 μL template DNA, 1 U DNA polymerase, and 0.1 μCi α-32P dCTP (NEN, U.S.A.).

After adding 20 μL of mineral oil (Sigma, U.S.A.), 35 cycles were executed. Each cycle consisted of denaturation (94°C) for 1 min, annealing for 60 sec (58°C for exons 5/6 and 8/9, and 64°C for exons 4 and 7), and extension for 2 min (72°C), and was carried out in an automated DNA Thermal Cycler (Perkin-Elmer, France). Forty microliter of stop buffer (95% formamide, 10 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol) was added to the PCR product, and 2 μL of the final mixture was sampled. Samples were heated at 95°C for 5 min and immediately loaded onto a 6% non-denaturing polyacrylamide gel containing 6% glycerol. Gels were run at 30 W for 3 hr, cooled by fan at room temperature, dried at 60°C, and autoradiographed for 12-48 hr.

RT-PCR for EGFR gene amplification

To investigate the expression level of EGFR in human glioblastoma, we employed a reverse transcriptase (RT)-PCR assay using EGFR primers. Total RNA was extracted from the tumor tissues of each glioblastoma patient. After the reverse transcription, EGFR primers were used for cDNA amplification. RNA integrity was confirmed with
parallel RT-PCR amplification using \( \beta \)-actin primers. PCR products were electrophoresed on agarose gels containing ethidium bromide and visualized by UV photography. The detailed procedure was as follows.

Total RNA was extracted from frozen tissues using the LiCl/Urea method (26). For cDNA synthesis, 3 \( \mu \)L of total RNA was annealed to oligo (dT) 15 in 20 \( \mu \)L total volume containing 4 \( \mu \)L of 5 XM-MLV RT buffer (50 mM Tris-HCl, pH 8.3, 7.5 mM KCl, 3 mM MgCl\(_2\), and 10 mM DTT), 0.5 mM dNTP, 20 U RNase and 200 U M-MLV RT (Promega, Germany) and was incubated at 37 \( ^\circ \)C for 1.5 hr. PCR mixture contained 1X PCR buffer (50 mM KCl, 10 mM Tris-HCl, pH 9.0, and 0.1% Triton X-100), 1 mM MgCl\(_2\), 0.2 \( \mu \)M of each primer, 0.2 mM dNTP, 2.5 U of Taq DNA polymerase (Promega, Germany) and 1.5 \( \mu \)L of cDNA in a final volume of 50 \( \mu \)L. The amplification was performed in the DNA Thermal Cycler. Twenty-five PCR cycles were performed which consisted of 1 min at each temperature (94 \( ^\circ \)C, 53 \( ^\circ \)C, 72 \( ^\circ \)C), except for the initial cycle (5 min at 94 \( ^\circ \)C) and the final extension step (5 min at 72 \( ^\circ \)C). Primer sequences for EGFR and \( \beta \)-actin (reference gene) were as follows: 5'-AGCCATGCCCGCATTAGCTC-3' (5' primer) and 5'-AAAGGAATGCAACTTCCCAA-3' (3' primer) for EGFR (24) resulting in a 110-bp PCR product, 5'-GACTATGACTTAGTTGCGTTA-3' (5' primer) and 5'-GCCTTCATACATCTCAAGTTG-3' (3' primer) for \( \beta \)-actin resulting in a 501-bp PCR product.

**Statistical Analysis**

All statistical analysis was performed using Statistical Package for the Social Sciences (SPSS/PC + 7.5, Chicago, IL, U.S.A.). A \( p \) value of less than 0.05 was accepted as statistically significant. The Student t-test was used to evaluate differences in the age of patients and p53 labeling index (LI) between primary and secondary glioblastomas. The chi-square and Fisher's exact tests were used to analyze differences in sex ratio, p53 mutations, p53 expression, EGFR amplification, and EGFR expression.

---

**RESULTS**

The results of this study are summarized in Table 4. The mean ages of the patients with primary and secondary glioblastomas at the time of surgery were 50.2 ± 8.4 yr and 41.5 ± 10.4 yr respectively. The mean age of the patients with primary glioblastomas was significantly higher than that with secondary glioblastomas. The frequencies of both primary and secondary glioblastoma were higher in males than in females but the difference was not statistically significant.

p53 mutations were detected in 3 out of 15 (20.0%) primary glioblastomas (Fig. 1) and in 13 out of 21 (61.9%) secondary glioblastomas (p=0.014). All mutations were located between exons 5 to 9. Immunoreactivity to the p53 gene product was expressed on nuclei of glioblastoma cells. The distribution of p53-positive cells was very heterogeneous in many cases (Fig. 2), and there was no specific rela-

---

**Fig. 1.** Presence of exon 7 DNA of the p53 gene in glioblastomas by PCR (A), and mutations (*) revealed by single stranded conformational polymorphism (Lane 1-11; secondary glioblastoma cases).
Cytogenetic Changes in Glioblastoma

Case revealed (both positive, 30.6%; both negative, 61.1%). Only one activity was observed in 33 out of 36 (91.7%) glioblastomas amplification by RT-PCR and EGFR immunoreactivity was noted in 10 out of 15 (66.7%) primary glioblastomas (Table 1), and even absent in secondary glioblastomas (Table 2). EGFR immunoreactivity was noted along the cell membrane of glioblastoma cells. Among the 12 immunopositive cases, nine (75.0%) showed immunoreactivities in both low and high grade areas of glioblastomas while three (25.0%) showed only in high grade areas.

### DISCUSSION

The recent molecular biologic studies of astrocytic tumors suggest that both activation of oncogenes and inactivation of tumor suppressor genes are involved in the development of glioblastomas. Von Deimling et al. indicated that there were two types of glioblastomas based on their molecular biologic pathogenesis (27). The type 1 (secondary) glioblastoma occurs with LOH on chromosome 17p closely associated with p53 mutations and is more common in younger patients. The type 2 (primary) glioblastoma is characterized by higher frequencies of EGFR amplification and LOH on chromosome 10, and is common in elderly patients. The molecular features of primary and secondary glioblastomas were shown to be strongly correlated with the patients' clinical history in the recent studies (19, 27, 28).

Although some studies support the classification of glioblastomas into two subtypes, only a few studies have analyzed molecular genetic alterations of EGFR and p53 in association with immunohistochemical findings on tumor samples. According to our results, the mutations of the p53 gene were found in 20.0% of primary glioblastomas and 61.9% of secondary glioblastomas. This observation is consistent with the high rate of p53 mutations reported by Watanabe et al. (29). The high rate of p53 mutation in secondary glioblastomas might be due to the selection of biopsies according to the definite evidence of clinical progression from low grade or anaplastic astrocytomas. p53 protein immunoreactivity was noted in 33.3% and 80.1% of primary and secondary glioblastomas, respectively. In the presence of p53 gene mutations, positive staining of tumor cells for p53 protein might be expected; however, correlative studies of p53 protein immunohistochemistry and p53 gene mutation in glioblastomas reported a higher rate of protein expression than the gene mutation (30, 31). The results of this study suggest that an alternative mechanism of p53 gene mutation can result in p53 protein accumulation. In this study, p53 LI was scored 5.7±4.4% and 10.8±8.3% in primary and secondary glioblastomas, respectively. There has been reported a wide range of nuclear staining of p53 in glioblastomas (23, 29), and the difference might be attributed to the divergent monoclonal antibodies or to the scoring system used in each study.

EGFR is a member of the tyrosine kinase family of cell surface receptors and demonstrates various levels of expression throughout the cellular development and in a variety of different cell types. The receptor can transduce signals into the cells upon: 1) interaction with ligands such as EGF,
transforming growth factor (TGF-β), amphiregulin or heparin-binding EGF; 2) truncation or mutation of extracellular and/or intracellular domains; and 3) amplification of a basal receptor activity in the absence of ligand through cooperation with other cellular signaling pathways or nuclear events, such as an expression of v-erbB (32, 33). EGFR has been implicated in human cancers, where it may contribute both to the initiation (glioblastoma) and progression (epithelial tumors) of the disease. It is frequently present in an amplified or over-expressed form in up to 30-40% of malignant gliomas (34, 35).

According to the present study, the incidence of EGFR amplification was 73.3% and 9.5% in primary and secondary glioblastomas, respectively. Recent studies on EGFR amplification in glioblastoma were carried out by sub-grouping as primary and secondary forms. Lang et al. (36) reported 5 cases out of 34 glioblastomas had EGFR amplification and LOH on chromosome 10 without p53 mutations. Watanabe et al. (29) demonstrated a 63% incidence of EGFR amplification in primary glioblastomas compared to that of only 10% in secondary glioblastomas. According to the present study, positive immunohistochemical stain-
ings for EGFR were observed in 66.7% and 9.5% of primary and secondary glioblastomas, respectively. Correlative studies between EGFR gene amplification and immunohistochemical finding are rare. A comparative study by Rieske et al. (37) reported 13 cases (45%) with immunopositivity for EGFR in a series of 28 glioblastomas, while amplification of EGFR gene was observed in 12 cases. In this study, only one case showed no EGFR immunoreactivity in the presence of EGFR gene amplification, and two cases demonstrated weak EGFR immunoreactivity without EGFR gene amplification. There seems to be no strict correlations between EGFR gene amplification and the protein overexpression. EGFR was relatively well expressed in both low grade and high grade areas of glioblastomas, despite a few exceptional cases. Three out of 12 EGFR immunopositive cases were not stained in low grade areas. Concerning with the morphological heterogeneity of glioblastoma, the other study (38) reported that genetic abnormalities seen in the low grade areas were conserved in the high grade areas suggesting that these morphologically different cellular subsets were derived from a common transformed clone. These findings might be helpful to detect the presence or absence of tumor cell infiltrations in the peripheral margin or edematous area of glioblastomas.

In this study, the p53 mutation with concomitant EGFR gene amplification was observed in 13.3% of primary glioblastoma. There were no such cases among secondary glioblastomas. In line with this observation, Watanabe et al. reported only one case with such profile out of 20 secondary glioblastomas and none in 19 primary glioblastomas (29). These data indicate that EGFR amplification and p53 mutation are two different genetic events in the development of glioblastomas.

REFERENCES

1. Russell DS, Rubinstein LJ. Pathology of tumors of the central nervous system. London, Arnold, 1989.
2. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 1987; 59: 1617-25.
3. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer 1988; 62: 2152-65.
4. James CD, Carlbom E, Dumanski JP, Hansen M, Nordenskjold M, Collins VP, Cavenee WK. Clonal genomic alterations in glioma malignancy stages. Cancer Res 1988; 48: 5546-51.
5. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993; 3: 19-26.
6. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumors. Brain Pathol 1993; 3: 255-68.
7. Giani C, Finocchiaro G. Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res 1994; 54: 6338-9.
8. Louis DN. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 1994; 53: 11-21.
9. Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol Berl 1997; 94: 303-9.
10. Biernat W, Debic-Rychter M, Libeski PP. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas. Pol J Pathol 1998; 49: 267-71.
11. Hurtt MR, Moosy J, Donovan-Peluso M, Locker J. Amplification of epidermal growth factor receptor gene in gliomas: Histopathology and prognosis. J Neuropathol Exp Neurol 1992; 51: 84-90.
12. Ekstrand AI, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991; 51: 2164-72.
13. von Deimling A, Louis DN, von Ammon K, Wiestler OD, Seizinger BR. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 1992; 52: 4277-9.
14. Bello MJ, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Saenz-Castresana J, Pestana A, Rey JA. Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglium tumors. Int J Cancer 1994; 57: 172-5.
15. Kraus JA, Koopmann J, Kaskel P, Mainz D, Brandner S, Schramm J, Louis DN, Wiestler OD. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropath Exp Neurol 1995; 54: 91-5.
16. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendrogliomas shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994; 145: 1175-90.
17. Chung R, Whaley J, Kley N, Anderson K, Louis D, Menon A, Hetlich C, Freiman R, Hedley-Whyte ET, Martuza R. TP53 gene mutations and 17p deletions in human astrocytomas. Genes Chromosomes Cancer 1991; 3: 323-31.
18. Rasheed BK, McLendon RE, Hendon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH. Alterations of the TP53 gene in human gliomas. Cancer Res 1994; 54: 1324-30.
19. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993; 3: 19-26.
20. von Deimling A, Louis DN, von Ammon K, Petersen I, Hoell T, Chung Ry, Martuza RL, Schoenfeld DA, Yasargill MG, Wiestler OD. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 1992; 77: 295-301.
21. Reed JA, Manahan LJ, Park CS, Brigati DJ. Complete one-hour immunohistochemistry based on capillary action. Biotechniques 1993; 13: 434-43.
22. Cheng Y, Ng HK, Ding M, Zhang SF, Pung C, Lo KW. Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors. J Neuropathol Exp Neurol 1999; 58: 120-8.
23. Ng HK, Lo SY, Huang DP, Poon WS. Paraffin section p53 protein immunohistochemistry in neuroectodermal tumors. Pathology 1994; 26: 1-5.

24. Reifenberger J, Ring GU, Gies U, Cobbers L, Oberstrass J, An HX, Niederacher D, Wechsler W, Reifenberger G. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 1996; 55: 822-31.

25. Brustle O, Ohgaki H, Schmitt HP, Walter GF, Ostertag H, Kleihues P. Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children. Association with an activated K-ras gene. Cancer 1992; 69: 2385-92.

26. Neubauer A, Neubauer B, He M, Effert P, Iglehart D, Frye RA, Liu E. Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene 1992; 7: 1019-25.

27. von Deimling A, Louis DN, Wiestler OD. Molecular pathways in the formation of gliomas. Glia 1995; 15: 328-38.

28. Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H. Loss of heterozygosity on chromosome 19 in secondary glioblastoma. J Neuropathol Exp Neurol 2000; 59: 539-43.

29. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6: 217-23.

30. Newcomb EW, Madonia WJ, Pisharody S, Lang FF, Koslow M, Miller DC. A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol 1993; 3: 229-35.

31. Lang FF, Miller DC, Pisharody S, Koslow M, Newcomb EW. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene 1994; 9: 949-54.

32. Khazaie K, Schirmacher V, Lichtner RB. EGF receptor in neoplasia and metastasis. Cancer Metast Rev 1993; 12: 255-74.

33. Downward J, Yarden Y, Mayes E, Scrase G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield MD. Close similarity of the epidermal growth factor receptor and the v-erb-B oncogene protein sequences. Nature 1984; 307: 521-7.

34. Collins VP. Amplified genes in human gliomas. Semin Cancer Biol 1993; 4: 27-32.

35. Ohgaki H, Schauble B, zur Hausen A, von Ammon K, Kleihues P. Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 1995; 427: 113-8.

36. Lang FF, Miller DC, Koslow M, Newcomb EW. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 1994; 81: 427-36.

37. Rieske P, Kordek R, Bartkowiak J, Debiec-Rychter M, Bienhat W, Liberski PP. A comparative study of epidermal growth factor receptor (EGFR) and MDM2 gene amplification and protein immunoreactivity in human glioblastomas. Pol J Pathol 1998; 49: 145-9.

38. Cheng Y, Ng HK, Ding M, Zhang SF, Pang JC, Lo KW. Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors. J Neuropathol Exp Neurol 1999; 58: 120-8.